Showing 4741-4750 of 6036 results for "".
- Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trials for Presbyopia and Dry Eye Diseasehttps://modernod.com/news/glaukos-announces-first-patient-enrolled-in-phase-2-clinical-trial-for-presbyopia/2480564/Glaukos announced that it has enrolled the first patient into a phase 2 clinical trial of GLK-302 for the treatment of presbyopia and GLK-301 for the treatment of signs and symptoms of dry eye disease (DED). GLK-302 is the second investigational drug candidate utilizing Glaukos&rsq
- Alcon Completes Acquisition of Ivantis, Bringing Hydrus Microstent into Its Global Surgical Portfoliohttps://modernod.com/news/alcon-completes-acquisition-of-ivantis-bringing-hydrus-microstent-into-its-global-surgical-portfolio/2480555/Alcon announced the closing of its previously announced acquisition of Ivantis, developer of the Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients in connection with cataract surge
- Glaukos Announces FDA 510(k) Clearance of iPRIME Viscodelivery Systemhttps://modernod.com/news/glaukos-announces-fda-510k-clearance-of-iprime-viscodelivery-system/2480553/Glaukos announced that it has received 510(k) clearance from the FDA for the iPRIME Viscodelivery System, a sterile, single-use, minimally-invasive device for the delivery of viscoelastic fluid during ophthalmic surgery. “Since the introduction of our first&nb
- Kriya Expands Gene Therapy Pipeline and Establishes Its Rare Disease Therapeutic Area Division with Acquisition of Warden Biohttps://modernod.com/news/kriya-expands-gene-therapy-pipeline-and-establishes-its-rare-disease-therapeutic-area-division-with-the-acquisition-of-warden-bio/2480550/Gene therapy company Kriya Therapeutics announced that it has acquired Warden Bio, a company developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs). Under the agreement, Kriya has obtained exclusive rights to Warden Bio’s five preclinical gene therapy programs.</
- EyeQue Launches MyReaderNumber App: Personalized Results for Reading and Computer Glasseshttps://modernod.com/news/eyeque-launches-myreadernumber-app-personalized-results-for-reading-and-computer-glasses/2480543/EyeQue introduced a first-of-its-kind smartphone app called MyReaderNumber that offers AR technology vision testing for presbyopia. EyeQue’s new AR-powered MyReaderNumber app delivers personalized measurements for both near reading distance and mid-distance (computer us
- New Survey From Bausch + Lomb and Glaucoma Research Foundation Reveals Emotional and Social Impact of Hyperemia on Glaucoma Patientshttps://modernod.com/news/new-survey-from-bausch-lomb-and-glaucoma-research-foundation-reveals-emotional-and-social-impact-of-hyperemia-on-glaucoma-patients/2480542/Bausch + Lomb and Glaucoma Research Foundation (GRF) released new key findings from a survey of glaucoma patients that was designed to gain a greater understanding of the impact that hyperemia can have in the treatment and lives of people living with glaucoma. In the Unit
- AffaMed Therapeutics Enters into a Licensing Agreement with Hanmi Pharmaceutical for Investigational Dry AMD Treatment in Greater Chinahttps://modernod.com/news/affamed-therapeutics-enters-into-a-licensing-agreement-with-hanmi-pharmaceutical-for-investigational-dry-amd-treatment-in-greater-china/2480540/AffaMed Therapeutics announced that it has entered into a licensing agreement with Hanmi Pharmaceutical Co. Through this partnership, AffaMed obtains exclusive rights to manufacture, develop, and commercialize first-in-class ophthalmic intravitreal injectable product Risuteganib (Luminate) t
- Novartis Acquires Gyroscope Therapeutics, Maker of Investigational Gene Therapy for Geographic Atrophyhttps://modernod.com/news/novartis-acquires-gyroscope-therapeutics-maker-of-investigational-gene-therapy-for-geographic-atrophy/2480532/Novartis has bolstered it gene therapy portfolio after entering into a definitive agreement to acquire all of the outstanding share capital of the UK-based ocular gene therapy company Gyroscope Therapeutics. Novartis will make an upfront payment of $800 million and potential additi
- Glaukos Announces Retirement of William J. Link, PhD, as Chairman of the Board; and Election of Thomas W. Burns as New Chairmanhttps://modernod.com/news/glaukos-announces-retirement-of-william-j-link-phd-as-chairman-of-the-board-and-election-of-thomas-w-burns-as-new-chairman/2480530/Glaukos announced that William J. Link, PhD, will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos’ Board and has served as Chairman since June 2001. In connection with Dr. Link’s retirement, the Board has appointed Thomas W. Burns, Glaukos&rs
- Foundation Fighting Blindness and Nixon Visions Foundation Collaborate to Combat Inherited Retinal Diseaseshttps://modernod.com/news/foundation-fighting-blindness-and-nixon-visions-foundation-collaborate-to-combat-inherited-retinal-diseases/2480523/The Foundation Fighting Blindness announced the launch of the Nixon Visions Foundation Inherited Macular Dystrophy Program formed through a collaboration with the Nixon Visions Foundation. The program will provide funding for six early translational research projects over 3 years for the dev